5家被SEC列入“預摘牌名單”股票全線重挫!涉及一家A股
格隆匯3月11日丨美國證監會(SEC)昨晚發佈消息,依據《外國公司問責法》認定五家在美上市公司(百勝中國、百濟神州、再鼎醫藥、和黃醫藥、ACM Research)為有退市風險的“相關發行人”。今日港股市場再鼎醫藥-SB跌近15%,和黃醫藥跌超12%,百勝中國-S跌近11%,百濟神州跌超9%,A股市場的盛美上海跌超8%。再鼎醫藥-SB今早發公吿迴應稱,公司被暫時性認定並不意味着公司將會被SEC從納斯達克交易所除牌。百濟神州迴應稱,一直在尋求解決方案以滿足《外國公司問責法案》的要求。盛美上海稱控股股東ACMR正在積極尋找解決方法,致力於滿足美國SEC要求。百勝中國在港交所稱,除非法案修訂將其排除或審計師進行全面核查,否則其普通股將於2024年初從紐約證券交易所退市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.